Innoviva/$INVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innoviva
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Ticker
$INVA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
127
ISIN
US45781M1018
Website
Innoviva Metrics
BasicAdvanced
$1.3B
-
-$0.95
0.36
-
Price and volume
Market cap
$1.3B
Beta
0.36
52-week high
$20.96
52-week low
$15.56
Average daily volume
694K
Financial strength
Current ratio
2.479
Quick ratio
2.236
Long term debt to equity
49.262
Total debt to equity
78.975
Interest coverage (TTM)
9.00%
Management effectiveness
Return on assets (TTM)
9.40%
Return on equity (TTM)
-8.84%
Valuation
Price to revenue (TTM)
3.535
Price to book
2.03
Price to tangible book (TTM)
3.07
Price to free cash flow (TTM)
6.67
Growth
Revenue change (TTM)
18.70%
Earnings per share change (TTM)
-142.34%
3-year revenue growth (CAGR)
-2.29%
3-year earnings per share growth (CAGR)
-23.93%
What the Analysts think about Innoviva
Analyst ratings (Buy, Hold, Sell) for Innoviva stock.
Innoviva Financial Performance
Revenues and expenses
Innoviva Earnings Performance
Company profitability
Innoviva News
AllArticlesVideos
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
Business Wire·2 weeks ago
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
GlobeNewsWire·2 weeks ago
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
24/7 Wall Street·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innoviva stock?
Innoviva (INVA) has a market cap of $1.3B as of June 05, 2025.
What is the P/E ratio for Innoviva stock?
The price to earnings (P/E) ratio for Innoviva (INVA) stock is 0 as of June 05, 2025.
Does Innoviva stock pay dividends?
No, Innoviva (INVA) stock does not pay dividends to its shareholders as of June 05, 2025.
When is the next Innoviva dividend payment date?
Innoviva (INVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innoviva?
Innoviva (INVA) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.